GLP-1 Receptor Agonists and Cardiovascular Outcomes in Obesity: What the Evidence Shows
Synthesising 8 major trials enrolling over 19,000 patients to determine whether GLP-1 receptor agonists reduce cardiovascular events in patients with obesity and overweight who do not have diabetes.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- Strong evidence from the landmark SELECT trial (n=17,604) supports GLP-1 receptor agonists for cardiovascular outcomes in obesity without diabetes: semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% (HR 0.80, 95% CI 0.72–0.90, p<0.001) over a mean 39.8 months of follow-up.
- The cardiovascular benefit was independent of baseline HbA1c and magnitude of HbA1c change, indicating that pleiotropic mechanisms beyond glucose lowering — including anti-inflammatory effects and reductions in epicardial adipose tissue — are responsible.
- The STEP-HFpEF programme demonstrated that semaglutide substantially improved symptoms, exercise capacity, and quality of life in patients with obesity-related heart failure with preserved ejection fraction, with consistent effects across obesity classes and age groups.
- SELECT exclusively enrolled patients with established atherosclerotic cardiovascular disease — whether GLP-1 receptor agonists provide primary cardiovascular prevention in obesity without established CVD remains unproven. Discontinuation rates (16.6% semaglutide vs 8.2% placebo) raise durability questions. Through 2025.
Why GLP-1 Receptor Agonists and Cardiovascular Risk in Obesity Matters
Obesity affects over 650 million adults globally and is independently associated with cardiovascular morbidity and mortality beyond its contribution to diabetes, hypertension, and dyslipidaemia. Despite this, the concept of pharmacologically treating obesity to reduce cardiovascular events was, until recently, unsupported by outcome trial data. Previous weight-loss agents such as sibutramine, rimonabant, and lorcaserin either failed to demonstrate cardiovascular benefit or were withdrawn due to safety concerns.
The SELECT trial’s demonstration that semaglutide reduces MACE in patients with obesity and established cardiovascular disease — without diabetes — represents a paradigm shift. For the first time, obesity is validated as a modifiable cardiovascular risk factor amenable to pharmacological intervention. This evidence review synthesises SELECT alongside the STEP-HFpEF programme and supporting mechanistic data to assess the current evidence base.
What Evidence Was Reviewed
This synthesis centres on the SELECT cardiovascular outcome trial and the STEP-HFpEF programme, supplemented by supporting sub-analyses and the broader GLP-1 receptor agonist evidence base from diabetes trials that informed the clinical rationale. Together, these studies provide a comprehensive view of semaglutide’s cardiovascular effects in the context of obesity.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| SELECT (2023) | RCT | 17,604 | BMI ≥27, established CVD, no diabetes | MACE HR 0.80 (95% CI 0.72–0.90); 20% risk reduction; 9.4% mean weight loss | High |
| SELECT — HbA1c sub-analysis (2024) | Pre-specified sub-analysis | 17,604 | Same, stratified by baseline HbA1c | Benefit consistent across normoglycaemic, pre-diabetic, and near-threshold HbA1c groups; independent of HbA1c change | High |
| SELECT — HF sub-analysis (2024) | Pre-specified sub-analysis | 17,604 | Participants with baseline HF (24%) | MACE HR 0.65 (HFrEF) and 0.69 (HFpEF); composite HF endpoints also improved | High |
| SELECT — Sex sub-analysis (2024) | Pre-specified sub-analysis | 17,604 | 72.3% male, 27.7% female | Greater weight loss in women (−11.1% vs −7.5%); CV benefit directionally consistent; women had lower baseline event rates | Moderate |
| STEP-HFpEF (2023) | RCT | 529 | Obesity-related HFpEF, no diabetes | Improved KCCQ-CSS (+7.8 points), 6MWD (+20.3m), body weight (−13.3%); reduced CRP (−43.5%) | High |
| STEP-HFpEF DM (2024) | RCT | 616 | Obesity-related HFpEF + type 2 diabetes | Similar symptom, functional, and weight improvements; consistent across HbA1c levels | High |
| Pooled STEP-HFpEF (2024) | Pooled RCT analysis | 1,145 | Combined STEP-HFpEF trials | Consistent benefit across age groups, LVEF categories, and obesity classes; proportional to weight loss | High |
| GLP-1 RA meta-analysis (diabetes trials) | Meta-analysis of 8 CVOTs | 60,080 | Type 2 diabetes + CV risk | 14% MACE reduction as class (HR 0.86, 95% CI 0.80–0.93); established cardiovascular class effect | High |
Key Findings: GLP-1 Receptor Agonists and Cardiovascular Protection in Obesity
SELECT: The First Cardiovascular Outcome Trial for Obesity Without Diabetes
SELECT enrolled 17,604 adults aged ≥45 with established atherosclerotic cardiovascular disease (76% with prior MI, 18% with prior stroke, 24% with peripheral artery disease) and BMI ≥27 but without diabetes. Participants received semaglutide 2.4 mg subcutaneously once weekly or placebo, escalated over 16 weeks to the target dose. Mean baseline HbA1c was 5.8%, with 66.4% meeting criteria for prediabetes. Over a mean follow-up of 39.8 months, semaglutide reduced the primary composite of cardiovascular death, non-fatal MI, or non-fatal stroke by 20% (HR 0.80, 95% CI 0.72–0.90, p<0.001).
The cardiovascular benefit appeared early — the separation in event curves emerged within the first year, well before maximal weight loss was achieved. This temporal pattern, combined with the HbA1c sub-analysis showing benefit independent of glycaemic change, points toward mechanisms beyond weight loss and glucose lowering. Semaglutide treatment was associated with 9.4% mean body weight loss, reductions in blood pressure, improvements in lipid profiles, and a substantial decrease in high-sensitivity CRP (approximately 35–40%), suggesting that anti-inflammatory and anti-atherosclerotic effects contribute meaningfully to the cardiovascular protection.
Heart Failure Outcomes: SELECT and STEP-HFpEF Converge
Heart failure was present in 24% of SELECT participants at baseline. A pre-specified sub-analysis revealed that semaglutide reduced MACE in both HFrEF (HR 0.65, 95% CI 0.49–0.87) and HFpEF (HR 0.69, 95% CI 0.51–0.91) subgroups. Serious adverse events were less frequent with semaglutide regardless of heart failure subtype, addressing prior safety concerns about GLP-1 receptor agonists in heart failure that had been raised by earlier liraglutide trials (FIGHT, LIVE).
The STEP-HFpEF programme provided complementary evidence, demonstrating that semaglutide 2.4 mg substantially improved HF-related symptoms (KCCQ-CSS improvement of 7.8 points), exercise capacity (6MWD gain of 20.3 metres), and reduced inflammation (CRP reduction of 43.5%) in patients with obesity-related HFpEF over 52 weeks. The pooled analysis of STEP-HFpEF and STEP-HFpEF DM (n=1,145) confirmed consistent benefits across obesity classes I–III, all LVEF categories (45–49%, 50–59%, ≥60%), and the full age spectrum. The magnitude of symptomatic improvement was proportional to the extent of weight loss.
Pre-clinical and translational data suggest multiple pathways through which GLP-1 receptor agonists may confer cardiovascular protection independently of glycaemic control. These include direct anti-inflammatory effects (reducing macrophage infiltration and pro-inflammatory cytokine release), improvement in endothelial function, reduction in vascular smooth muscle cell migration and proliferation, promotion of atherosclerotic plaque stability, and reduced platelet aggregation. Semaglutide has also been shown to reduce epicardial and perivascular adipose tissue — deposits with established pro-inflammatory and pro-atherogenic properties. The early separation of MACE curves in SELECT, preceding maximal weight loss, and the HbA1c-independent benefit are both consistent with these direct vascular effects contributing to the observed cardiovascular protection.
Women represented 27.7% of SELECT participants — a limitation reflecting the predominantly male composition of secondary cardiovascular prevention populations. A pre-specified sex-based analysis revealed that women experienced greater weight loss (−11.1% vs −7.5%) and waist circumference reduction (−8.2 cm vs −5.9 cm) than men. The hsCRP reduction was also more pronounced in women (−46% vs −35%). Despite a higher burden of traditional risk factors, women had lower absolute event rates than men, making statistical power for the MACE endpoint more limited. The cardiovascular benefit appeared directionally consistent, but the lower event rates and smaller sample size limit definitive conclusions about the magnitude of benefit in women specifically.
Gastrointestinal adverse events — primarily nausea, diarrhoea, and vomiting — were the most common side effects and drove the higher discontinuation rate with semaglutide (16.6% vs 8.2% placebo). These symptoms were typically most prominent during dose escalation and often attenuated with continued use. Gallbladder disorders were slightly more common with semaglutide (2.8% vs 2.3%), consistent with prior GLP-1 receptor agonist data. Importantly, there was no increase in severe gastrointestinal disorders, pancreatitis, psychiatric events, or kidney injury. The overall rate of serious adverse events was actually lower with semaglutide than placebo in both the overall population and in heart failure subgroups. The 16.6% permanent discontinuation rate is clinically significant and raises questions about long-term adherence in real-world settings outside the structured trial environment.
SELECT demonstrated renal protective effects, with semaglutide slowing the annual decline in eGFR. The total eGFR slope was 0.75 mL/min/1.73 m² per year less with semaglutide than placebo. This effect was observed in both men and women, though with slightly greater magnitude in women (0.54 vs 0.33 mL/min/1.73 m² per year). These findings extend the kidney-protective signal observed with GLP-1 receptor agonists in diabetes trials to the non-diabetic obese population and suggest potential benefit across the cardiorenal-metabolic spectrum. Dedicated kidney outcome trials of GLP-1 receptor agonists are underway.
Quality & Consistency of Evidence
What the Evidence Does NOT Show
Despite SELECT’s landmark status, several important clinical questions remain unanswered.
Primary cardiovascular prevention: SELECT enrolled exclusively patients with established atherosclerotic CVD. Whether semaglutide reduces first cardiovascular events in obese individuals without prior MI, stroke, or PAD is not established. This is the most critical gap in the evidence base for broad clinical application.
Durability after discontinuation: SELECT was a treatment trial, not a stop-and-continue study. Weight regain after GLP-1 receptor agonist discontinuation is well documented, and the permanence of cardiovascular benefit after treatment cessation is unknown. The relatively high discontinuation rate (16.6%) amplifies this concern for real-world effectiveness.
Comparative effectiveness with other GLP-1 RAs or tirzepatide: Only semaglutide 2.4 mg has demonstrated MACE reduction in non-diabetic obesity. Whether liraglutide, dulaglutide, or the dual GIP/GLP-1 agonist tirzepatide confer similar cardiovascular protection in this population is unknown. Head-to-head CVOT data are absent.
Cost-effectiveness and health equity: At current pricing, semaglutide 2.4 mg represents a substantial long-term cost. Whether the cardiovascular benefits translate into cost-effective treatment across diverse healthcare systems and socioeconomic groups has not been established. Access disparities may limit the population-level impact of these findings.
Practical Implications
Based on the current evidence, the following considerations emerge for clinicians managing cardiovascular risk in patients with obesity.
SELECT provides the first evidence that pharmacological treatment of obesity reduces cardiovascular events. For patients with established atherosclerotic CVD, BMI ≥27, and no diabetes, semaglutide 2.4 mg weekly reduces 3-point MACE by 20%. This benefit is additive to standard secondary prevention (statins, antihypertensives, antiplatelet agents).
The cardiovascular protection was consistent across normoglycaemic (HbA1c <5.7%), prediabetic (5.7–6.0%), and near-threshold (6.0–6.5%) groups, and was independent of HbA1c change during treatment. The available evidence suggests that pleiotropic anti-inflammatory and vascular effects, rather than glucose lowering or weight loss alone, drive the cardiovascular benefit.
For patients with the obesity phenotype of HFpEF, semaglutide 2.4 mg improves symptoms, exercise function, and inflammation markers regardless of diabetes status, LVEF category, or degree of obesity. Benefits are proportional to weight loss achieved and consistent across the age spectrum.
The 16.6% discontinuation rate highlights the importance of gradual dose escalation over the full 16-week period. The available evidence indicates that gastrointestinal symptoms typically peak during escalation and diminish with continued therapy. Counselling patients about expected transient symptoms and slowing up-titration when needed may improve long-term adherence.
Evidence Grade & Bottom Line
Evidence Grade: Strong (for secondary prevention)
SELECT is a single trial but is large (n=17,604), well-designed, and event-driven with consistent results across all pre-specified subgroups. Supported by the established cardiovascular class effect from diabetes CVOTs and the STEP-HFpEF programme. For primary prevention in obesity, evidence is insufficient.
SELECT establishes obesity as a pharmacologically modifiable cardiovascular risk factor for the first time. For patients with established atherosclerotic CVD and BMI ≥27 without diabetes, semaglutide 2.4 mg should be considered alongside other evidence-based secondary prevention therapies. The evidence does not yet support extrapolation to primary prevention or to other GLP-1 receptor agonists in this indication.
- Semaglutide 2.4 mg weekly reduced MACE by 20% in patients with obesity and established CVD but without diabetes — the first anti-obesity agent to achieve this
- Cardiovascular benefit is independent of glucose lowering and appeared early, pointing to direct anti-inflammatory and vascular mechanisms
- STEP-HFpEF demonstrates substantial symptomatic and functional improvement in obesity-related HFpEF, consistent across obesity severity and age
- Additional benefits include 73% diabetes prevention, renal protection, and reduced inflammation
- Primary prevention data are absent, discontinuation rates are high (16.6%), cost barriers are substantial, and long-term durability after stopping treatment is unknown
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563
- Lingvay I, Deanfield J, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT. Diabetes Care. 2024;47(8):1360-1369. DOI: 10.2337/dc24-0764
- Butler J, Packer M, Siddiqi TJ, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10456):773-786. DOI: 10.1016/S0140-6736(24)01498-3
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. DOI: 10.1056/NEJMoa2306963
- Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394-1407. DOI: 10.1056/NEJMoa2313917
- Borlaug BA, Kitzman DW, Davies MJ, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;29(9):2358-2365. DOI: 10.1038/s41591-023-02526-x
- Kosiborod MN, Verma S, Borlaug BA, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials. Lancet. 2024;403(10437):1635-1648. DOI: 10.1016/S0140-6736(24)00469-0
- Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2021;9(10):653-662. DOI: 10.1016/S2213-8587(21)00203-5
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. DOI: 10.1056/NEJMoa1607141
- Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61-69. DOI: 10.1016/j.ahj.2020.07.008
- Lingvay I, Brown-Frandsen K, Colhoun HM, et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity. 2023;31(S1):111-122. DOI: 10.1002/oby.23621
- Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15-30. DOI: 10.1016/j.cmet.2016.06.009